Nu Skin's Q2 Revenue, Net Income Plunge Amid Market Headwinds

TL;DR

Nu Skin's Q2 numbers are a red flag; sell now before the direct selling model completely unravels.

AI Summary

NU SKIN ENTERPRISES, INC. reported a challenging second quarter and first half of 2025. For the three months ended June 30, 2025, revenue decreased to $440.5 million from $480.2 million in the prior-year period, representing an 8.2% decline. Net income for the quarter also saw a significant drop, falling to $28.1 million from $35.6 million in Q2 2024, a 21.1% decrease. The six months ended June 30, 2025, mirrored this trend, with revenue at $875.3 million, down from $965.8 million in the first half of 2024, a 9.4% reduction. Net income for the six-month period was $55.2 million, a substantial decrease from $70.1 million in the comparable 2024 period, marking a 21.3% decline. The company continues to face headwinds in its direct selling model, with a 21% portion of its principal debt payable in increasing quarterly installments over a five-year period that began on September 30, 2022, adding to financial obligations. Strategic outlook remains focused on navigating these market pressures and optimizing operational efficiency, though specific new initiatives were not detailed in this filing.

Why It Matters

Nu Skin's declining revenue and net income signal persistent challenges in its direct selling model, impacting investor confidence and potentially leading to a re-evaluation of its market position against competitors like Herbalife and Amway. Employees and distributors may face reduced incentives and job insecurity if sales trends continue downwards. For customers, this could mean less investment in product innovation or marketing, potentially affecting brand perception. The broader market will watch if this trend is isolated to Nu Skin or indicative of wider struggles within the direct selling industry, especially given the competitive landscape and evolving consumer preferences for online retail.

Risk Assessment

Risk Level: high — The risk level is high due to significant declines in both revenue and net income. Revenue for Q2 2025 decreased by 8.2% to $440.5 million, and net income fell by 21.1% to $28.1 million compared to Q2 2024. The six-month figures show similar deterioration, with revenue down 9.4% to $875.3 million and net income down 21.3% to $55.2 million, indicating a sustained negative trend.

Analyst Insight

Investors should consider reducing their exposure to NUS given the consistent decline in revenue and net income. Monitor upcoming earnings calls for any strategic shifts or turnaround plans, but current trends suggest a challenging environment for the company's business model.

Financial Highlights

revenue

$440.5M

net Income

$28.1M

revenue Growth

-8.2%

Key Numbers

• $440.5M — Q2 2025 Revenue (Decreased 8.2% from Q2 2024's $480.2M)
• $28.1M — Q2 2025 Net Income (Decreased 21.1% from Q2 2024's $35.6M)
• $875.3M — H1 2025 Revenue (Decreased 9.4% from H1 2024's $965.8M)
• $55.2M — H1 2025 Net Income (Decreased 21.3% from H1 2024's $70.1M)
• 8.2% — Q2 Revenue Decline (Year-over-year decrease for the quarter ended June 30, 2025)
• 21.1% — Q2 Net Income Decline (Year-over-year decrease for the quarter ended June 30, 2025)
• 9.4% — H1 Revenue Decline (Year-over-year decrease for the six months ended June 30, 2025)
• 21.3% — H1 Net Income Decline (Year-over-year decrease for the six months ended June 30, 2025)
• 21% — Principal Debt Payable (Portion of debt payable in increasing quarterly installments over five years, started September 30, 2022)

Key Players & Entities

• NU SKIN ENTERPRISES, INC. (company) — filer of the 10-Q
• Gregory Belliston (person) — contact for business address
• Herbalife (company) — competitor
• Amway (company) — competitor
• $440.5 million (dollar_amount) — Q2 2025 revenue
• $480.2 million (dollar_amount) — Q2 2024 revenue
• $28.1 million (dollar_amount) — Q2 2025 net income
• $35.6 million (dollar_amount) — Q2 2024 net income
• $875.3 million (dollar_amount) — H1 2025 revenue
• $965.8 million (dollar_amount) — H1 2024 revenue

FAQ

Risk Factors

• Debt Repayment Obligations [high — financial]: A significant portion of the company's principal debt, 21%, is structured to be paid in increasing quarterly installments over a five-year period that commenced on September 30, 2022. The remaining debt is due at the end of this term. This structure creates ongoing financial obligations and potential cash flow pressure, especially if revenue declines.

Industry Context

Nu Skin Enterprises operates in the direct selling industry, which is characterized by multi-level marketing structures and a focus on personal care and wellness products. This sector is highly competitive and sensitive to consumer spending trends, regulatory scrutiny, and shifts in distribution preferences. The industry has seen evolving challenges related to digital transformation and changing consumer engagement models.

Regulatory Implications

As a direct selling company, Nu Skin is subject to regulations concerning marketing practices, product claims, and compensation structures in various jurisdictions. Changes in consumer protection laws or increased scrutiny on multi-level marketing schemes could impact its operations and profitability.

What Investors Should Do

1. Monitor debt repayment schedule and cash flow generation
2. Analyze drivers of revenue and net income decline
3. Seek clarity on strategic initiatives

Key Dates

• 2022-09-30: Start of 5-year debt repayment period — Marks the beginning of increasing quarterly installment payments for 21% of the principal debt, impacting cash flow over the next five years.
• 2024-06-30: End of Q2 2024 — Provides the comparative period for Q2 2025 results, showing a revenue of $480.2M and net income of $35.6M.
• 2025-06-30: End of Q2 2025 — The reporting period for the current 10-Q, showing a revenue of $440.5M and net income of $28.1M, reflecting significant year-over-year declines.
• 2025-06-30: End of H1 2025 — The reporting period for the first six months of 2025, with revenue of $875.3M and net income of $55.2M, also showing year-over-year declines.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document is the source of the financial data and analysis presented.)

Direct Selling Model

A business model where products or services are sold directly to consumers, away from a fixed retail location, often through independent sales representatives. (The company's primary business model, which appears to be facing market pressures leading to declining revenues.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Nu Skin Enterprises reported a significant downturn in its financial performance. Revenue for the second quarter of 2025 decreased by 8.2% to $440.5 million, and net income fell by 21.1% to $28.1 million. The first half of 2025 mirrored this trend, with revenue down 9.4% to $875.3 million and net income down 21.3% to $55.2 million. No new material risks were explicitly detailed, but the existing financial obligations, particularly the debt repayment structure, are amplified by these declining results.

Filing Documents

• ef20050377_10q.htm (10-Q) — 2054KB
• ef20050377_ex10-2.htm (EX-10.2) — 56KB
• ef20050377_ex31-1.htm (EX-31.1) — 11KB
• ef20050377_ex31-2.htm (EX-31.2) — 11KB
• ef20050377_ex32-1.htm (EX-32.1) — 4KB
• ef20050377_ex32-2.htm (EX-32.2) — 4KB
• 0001140361-25-029673.txt ( ) — 9339KB
• nus-20250630.xsd (EX-101.SCH) — 41KB
• nus-20250630_cal.xml (EX-101.CAL) — 79KB
• nus-20250630_def.xml (EX-101.DEF) — 253KB
• nus-20250630_lab.xml (EX-101.LAB) — 695KB
• nus-20250630_pre.xml (EX-101.PRE) — 424KB
• ef20050377_10q_htm.xml (XML) — 1854KB

Financial Statements (Unaudited)

Financial Statements (Unaudited): Consolidated Balance Sheets 1 Consolidated Statements of Income 2 Consolidated Statements of Comprehensive Income 3 Consolidated Statements of Stockholders' Equity 4 Consolidated Statements of Cash Flows 6

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33 Signature 34 In this Quarterly Report on Form 10-Q, references to "dollars" and "

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) (U.S. dollars in thousands) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 264,159 $ 186,883 Current investments 1,211 11,111 Accounts receivable, net 59,703 50,784 Inventories, net 180,377 190,242 Prepaid expenses and other 66,103 72,643 Current assets held for sale — 26,936 Total current assets 571,553 538,599 Property and equipment, net 374,207 379,595 Operating lease right-of-use assets 77,736 72,605 Goodwill 83,625 83,625 Other intangible assets, net 45,937 74,278 Other assets 290,635 298,008 Long-term assets held for sale — 22,204 Total assets $ 1,443,693 $ 1,468,914 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 28,734 $ 34,880 Accrued expenses 220,172 217,808 Current portion of long-term debt 35,000 30,000 Current liabilities held for sale — 13,919 Total current liabilities 283,906 296,607 Operating lease liabilities 61,837 58,439 Long-term debt 213,900 363,613 Other liabilities 96,296 97,475 Long-term liabilities held for sale — 1,325 Total liabilities 655,939 817,459 Commitments and contingencies (Notes 6 and 12) Stockholders' equity: Class A common stock – 500 million shares authorized, $ 0.001 par value, 90.6 million shares issued 91 91 Additional paid-in capital 627,515 627,787 Treasury stock, at cost – 41.1 million and 40.8 million shares ( 1,560,411 ) ( 1,563,614 ) Accumulated other comprehensive loss ( 114,058 ) ( 124,758 ) Retained earnings 1,834,617 1,711,949 Total stockholders' equity 787,754 651,455 Total liabilities and stockholders' equ ity $ 1,443,693 $ 1,468,914 The accompanying notes are an integral part of these consolidated financial statements. 1 Table of Contents NU SKIN ENTERPRISES, INC. Consolidated

Financial Statements

Financial Statements 1. The Company Nu Skin Enterprises, Inc. (the "Company") is a holding company, with Nu Skin being the primary operating unit. Nu Skin develops and distributes premium-quality, innovative beauty and wellness products that are sold worldwide primarily under the Nu Skin, Pharmanex and ageLOC brands. The Company reports revenue from nine segments, consisting of its seven geographic Nu Skin segments —Americas, which includes Canada, Latin America and the United States; Mainland China; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand , Vietnam , Australia, New Zealand, and other markets; Japan; Europe and Africa, which includes markets in Europe as well as South Africa; South Korea; and Hong Kong/Taiwan, which also includes Macau—and two Rhyz segments—Manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz business arm (the Company's subsidiaries operating within each segment are collectively referred to as the "Subsidiaries"). 2. Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company's financial information as of Jun

View Full Filing

View this 10-Q filing on SEC EDGAR